Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

Published:2013-10-25 Issue:6 Volume:2 Page:925-932
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Forero‐Torres Andres¹,Infante Jeffrey R.²,Waterhouse David³,Wong Lucas⁴,Vickers Selwyn⁵,Arrowsmith Edward⁶,He Aiwu Ruth⁷,Hart Lowell⁸,Trent David⁹,Wade James¹⁰,Jin Xiaoping¹¹,Wang Qiang¹¹,Austin TaShara¹¹,Rosen Michael¹¹,Beckman Robert¹¹,Roemeling Reinhard¹¹,Greenberg Jonathan¹¹,Saleh Mansoor¹²

Affiliation:

1. University of Alabama at Birmingham Birmingham Alabama

2. Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville Tennessee

3. Oncology Hematology Care Clinical Trials Cincinnati Ohio

4. Scott and White Hospital Temple Texas

5. University of Minnesota Minneapolis Minnesota

6. Chattanooga Oncology and Hematology Associates Chattanooga Tennessee

7. Lombardi Comprehensive Cancer Center Georgetown University Washington District of Columbia

8. Florida Cancer Specialists Fort Meyers Florida

9. Virginia Cancer Institute Richmond Virginia

10. Decatur Memorial Hospital Cancer Care Institute Decatur Illinois

11. Daiichi‐Sankyo Pharma Development Edison New Jersey

12. Georgia Cancer Specialists Atlanta Georgia

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.137

Reference30 articles.

1. Cancer statistics, 2012;Siegel R.;CA Cancer J. Clin.,2012

2. National Cancer Institute.2011.SEER stat fact sheets: pancreas. Available athttp://seer.cancer.gov/statfacts/html/pancreas.html(accessed 2 April 2012).

3. Improvements in survival and clinical benefit with gemcitabine as first‐line therapy for patients with advanced pancreas cancer: a randomized trial;Burris H. A.;J. Clin. Oncol.,1997

4. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

5. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical immunotherapy in pancreatic cancer;Cancer Immunology, Immunotherapy;2024-03-02

2. Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics;Biochemical Pharmacology;2024-03

3. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis;eLife;2024-01-24

4. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis;eLife;2024-01-24

5. Heparan sulfate promotes TRAIL-induced tumor cell apoptosis;2023-07-27